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Abstract
Background—It is widely accepted that chronic inflammation plays a role in the etiology of
colorectal cancer. Using a two-stage design, we examined the associations between colorectal
cancer and common variation in 37 key genes in the inflammation and innate immunity pathways.
Methods—In the discovery stage, 2,322 discordant sibships (2,535 cases, 3,915 sibling controls)
from the Colorectal Cancer Family Registry were genotyped for over 600 tagSNPs and 99 SNPs
were selected for further examination based on strength of association. In the second stage, 351
SNPs tagging gene regions covered by the 99 SNPs were tested in 4,783 Multiethnic Cohort
subjects (2,153 cases, 2,630 controls).
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Results—The association between rs9858822 in the PPARG gene and colorectal cancer was
statistically significant at the end of the second stage (odds ratio per allele = 1.36, Bonferroni-
adjusted P = 0.045), based on the “effective” number of markers in Stage 2 (n = 306). The risk
allele C was common (frequency 0.3) in African Americans but rare (frequency < 0.03) in whites,
Japanese Americans, Latinos and Native Hawaiians. No statistically significant heterogeneity of
effects across race/ethnicity, BMI levels, regular aspirin use or pack-years of smoking was
detected for this SNP. Suggestive associations were also observed for several SNPs in close
vicinity to rs9858822.
Conclusions—Our results provide new evidence of association between PPARG variants and
colorectal cancer risk.
Impact—Further replication in independent samples is warranted.
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Introduction
Chronic inflammation and innate immunity have been strongly implicated in cancer
development since Virchow first proposed a connection (1). The elimination of early
neoplastic cells through the cytotoxic activity of tumor-infiltrating T cells or intra-epithelial
lymphocytes is now a well-established host-defense mechanism against cancer (2, 3).
Normal inflammation is an integral part of the immune response to foreign antigens. It is
self-limiting and is initiated by pro-inflammatory cytokines and subsequently resolved by
anti-inflammatory cytokines (4). Dysregulation of the two types of molecules may lead to
chronic inflammation, a consequence of the inability of tissues to remove the irritant
(including the initial tumor cells) (2–6). Chronic inflammation is characterized by the
infiltration of damaged tissue by immune cells together with tissue destruction and constant
attempts to repair (7). The cytokines and chemokines produced in chronic inflammation and
chronic immune activation may affect tumor formation at various stages via induction of
reactive oxygen species capable of oxidizing DNA, promoting tumor cell proliferation and
survival, stimulating angiogenesis, providing the tools and path for tumor cells (as well as
for leucocytes) migration, etc. (1).
Colorectal cancer (CRC) is a particularly relevant disease to study the links between
inflammation and cancer because of the importance of the immune system in the
maintenance of homeostasis in the normal gut and because of its strong associations with
inflammatory bowel disease and non-steroidal anti-inflammatory drug use (8). In this study,
we tested the hypothesis that common variants in 37 key genes involved in the inflammation
and innate immunity pathways may result in predisposition to CRC, by examining
associations between disease status and >600 tagSNPs in these genes (as well as 79
additional genetic risk variants with published evidence for association) in two large
observational studies in two stages. We performed both single-variant and pathway-based
analysis and took into account SNP correlation and gene correlation. Our approach is more
comprehensive than past studies that mostly focused on single genes or single
polymorphisms ((9–15)). The advantage of our approach over genome-wide association
studies is that by utilizing prior biological knowledge, the burden of multiple comparison
adjustment is reduced so that the power of identifying genuine but modest effects is
enhanced.
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Stage 1 SNP selection, subjects and genotypes
The 37 genes are related to tumor infiltrating and cytotoxic activity, pattern recognition
receptors, pro- and anti-inflammatory cytokines and chemokines, the nuclear factor kappa-B
pathway and prostaglandin synthesis (Supplementary Table 1). Due to LD structure and
proximity between genes, tagSNPs were selected for 34 gene regions (including 5kb
upstream and 10kb downstream) with r2 > 0.8 based on HapMap or SeattleSNPs data (all in
Europeans). TagSNPs were filtered based on minor allele frequency (MAF) (>0.05) and
Illumina design score (>0.4), except that non-synonymous/missense variants were forced
into the selection. 79 SNPs in relevant pathways reported to be associated with CRC were
also included, bringing the number of selected SNPs to 768.
The first stage was conducted in the Colorectal Cancer Family Registry (CCFR) using a
case-unaffected-sibling-control design. The CCFR is a consortium of six family registries in
the United States, Australia and Canada that consist of patients and their families who
represent the continuum of risk for CRC. Cases, ascertained from population-based cancer
registries and family clinics, were probands with a diagnosis of invasive adenocarcinoma of
the colon or rectum and controls were siblings with no history of CRC. Data on important
covariates were available from risk factor questionnaires of similar format across all sites.
Further information can be found elsewhere (16).
A total of 724 SNPs of the 768 SNPs (94%) were successfully genotyped for 7,086 CCFR
subjects (all available sibships in CCFR with at least one CRC-discordant pair with available
DNA) at the Translational Genomics Research Institute (TGen, Phoenix, AZ) using the
Illumina GoldenGate technology. The average concordance rate was 99.8% among
replicates. We employed strict quality controls (QC) similar to those in genome-wide
association studies (details in Supplementary Data) and included 6,450 subjects (2,355
cases, 4,095 controls) on 616 SNPs for analysis. 537 SNPs can be grouped into 34 gene
regions to account for long-range LD structure (see Supplementary Table 1 for gene names
and locations), excluding the 79 SNPs with previous evidence of association.
Stage 1 analysis
Conditional logistic regression was used to test for associations between single SNPs (count
of minor alleles) and CRC, adjusting for age and gender. Known CRC risk factors (listed in
Supplementary Data) did not substantially change OR estimates (<20%) and were not
included as covariates. We screened for interactions between SNPs and BMI (quartiles),
gender, aspirin use (ever/never taken aspirin ≥ twice per week for > one month) and pack-
years of smoking (0, ≤20, >20), and for interactions between SNPs from different gene
regions (>1Mb apart) using cross-product terms. Imputation of un-typed SNPs was
performed with BEAGLE 3.2 (17) and the Europeans in the 1000 Genomes Project, treating
siblings as independent since no imputation program has been designed for sib-ship data.
Only SNPs (n=2,305) with R2 > 0.9 were analyzed for main effects using expected allelic
dosages. We used arbitrary and liberal p-value thresholds (see Results) for promoting
markers with any main or interaction effects for further testing in Stage 2. A SNP-set
approach based on Kolmogorov-Smirnov-like running sums of ranked single-SNP χ2
statistics (18) was also implemented to examine the collective effect of all SNPs in a gene
(see Supplementary Data). Stage 1 analysis was mainly for discovery; the expectation was
that true genetic effects would appear as extreme statistics in some of the tests performed
would be followed up in the next stage. SAS (9.2) and R 2.10 were used in data analysis.
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Stage 2 SNP selection, subjects and genotypes
The second stage was conducted in the Multiethnic Cohort (MEC) (19). The MEC includes
215,000 men and women aged 45–75 at recruitment, primarily from five racial/ethnic
groups (African Americans, Japanese Americans, Latinos, Native Hawaiians and whites) in
Hawaii and California (19) (more details in Supplementary Data). Identification of incident
CRC cases is through linkage with the Hawaii Tumor Registry, the Los Angeles County
Cancer Surveillance Program and the State of California Cancer Registry. Controls were
randomly selected from the pool of MEC cancer-free subjects who provided a blood sample
and were frequency-matched to cases on age at cohort entry within each ethnic group. A
total of 2,237 CRC cases and 2,697 controls from the five groups with available DNA were
genotyped.
For the genetic regions covered by the promising variants from Stage 1, plus 5kb up- and
10kb down-stream, tagSNPs were selected to capture common variation (MAF > 0.05) with
r2 > 0.9 in the HapMap CEU (Europeans), ASW (African Americans), CHB (Chinese), JPT
(Japanese), MKK (Africans) and MEX (Mexicans). A sequential algorithm was used so that
tagSNPs selected for a previous population were forced into the subsequent round(s) of
selection. We note that genetic variation in Native Hawaiians, which are admixed with
Asian, European and Polynesian ancestries, may be less well covered since no Polynesian
population is included in any public datasets. A total of 384 tagSNPs were selected and 364
were successfully genotyped by TGen on the Illumina GoldenGate platform. The average
concordance rate was 99.5% among replicates pairs. After QC (details in Supplementary
Data), genotypes for 351 SNPs and 4,783 subjects (2,630 controls, 2,153 cases) were used in
analysis. Principal components (PCs) based on 93 ancestry informative markers (AIMs) that
separate major continental ancestries (20) were derived, except for 144 subjects for whom
AIMs genotyping was considered to have failed.
Stage 2 analysis
Logistic regression with adjustment for age, gender and racial/ethnic groups was performed
to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for each increase in allelic
count. Further adjustment for up to 8 PCs in the subset of data with PCs did not change ORs
importantly (change <4%), indicating that adjustment for self-reported race was sufficient to
control for potential population stratification; ORs in this subset were also similar to those
from the full data set. Adjusting additionally for CRC risk factors did not change ORs
substantially (change <13%). Thus, these covariates were not considered further in main-
effect analyses. Effect modification across race/ethnicity, BMI, regular aspirin use (yes/no),
and pack-years of smoking (0, ≤20, >20) was tested with a likelihood ratio test (LRT)
comparing models with and without the cross-product interaction terms, with further
adjustment for BMI, physical activity (average MET hours), total intake of red meat, pack-
years of smoking, aspirin use and daily intake of calcium and folate, where appropriate. Risk
factors were grouped based on tertiles unless otherwise specified. Heterogeneity across
anatomical sub-sites (left colon, right colon, and rectum) was tested using multinomial
logistic regression in SAS. Bonferroni correction was performed to adjust for multiple
comparisons at significance level 0.05 (2-sided) based on the number of independent/
effective markers estimated by the “Keffective” program (21): for each chromosome,
estimates were obtained for each ethnic group then the maximum among all groups was
taken; the sum of the maximums across all chromosomes was 306, leading to a single-test
significance threshold 1.63×10−4. Imputation was performed with BEAGLE (3.3) and ethnic
specific reference panels from the 1000 Genomes Project: ASN for Japanese Americans,
EUR for whites, EUR and AFR for African Americans, ASN and EUR for Native
Hawaiians, EUR and AMR for Latinos. Only markers (n=1,541) with R2 > 0.8 in all five
groups were kept for analysis. QC and data analysis was performed with PLINK (22) and R
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(2.13) except otherwise noted. All presented p-values are before Bonferroni correction,
unless otherwise specified.
Combining the two stages
When a SNP was available (i.e., was genotyped or passed imputation quality measures) in
both stages, a fixed-effect model was applied to combine ORs. I2 was calculated, where I2 >
25% indicates high level of heterogeneity. We used the combined ORs as a supplemental
index of the noteworthiness of a risk variant.
Summary effect of non-significant genes in Stage 2
To explore whether genes with no statistically significant single-variant association
contributed to CRC risk globally, we first selected the most important SNPs (conditional p-
values < 0.05) in these genes with stepwise regression, adjusting for sex and ethnicity
(missing values were replaced with mean dosage within sex and ethnic groups to preserve
sample size). The sum of the selected “risk” alleles (with OR>1) was then tested for
association with disease. The significance of this summary effect was assessed with
permutation: disease status was randomly shuffled within ethnicity and sex groups and the
above procedures were repeated for each permuted dataset; P-value was the proportion
among 4,000 permutated datasets for which the LRT statistics for the sum of the selected
“risk” alleles were greater than that observed in the original data.
RESULTS
Stage 1
The 2,322 discordant sibships from CCFR (n = 6,450) were of sizes 2 (54%), 3 (26%), 4
(12%), 5 (5%) and 6 to 13 (3%) and most (83%) were of European descent. The proportion
of men was 51.0% in cases and 44.6% in controls. Cases (mean = 55.1, SD =11.3) and
controls (mean = 53.8, SD = 11.8) were similar in age distribution. 1,535 sibships included
only colon cancer cases, 720 only rectal cancer and 67 both colon and rectal cancers. From
available parental information, 2 pairs of sibships (9 subjects) were related as half-sibs, and
44 parents and their siblings (total 124 subjects) were also present. Sensitivity analysis
showed that excluding the 133 subjects that complicated the sibship structure did not
materially alter the results. Model convergence was questionable for 15 SNPs among 616
analyzed SNPs due to sparse data so results were available for 601 markers. We used the
following criteria to promote 99 markers for further examination: 1) P <0.1 for genotyped
markers (n=49) or < 0.05 for imputed markers (n=31) in the main-effect analysis; 2) P <
0.001 for interactions between SNPs and risk factors (n=5); 3) P < 0.0001 for interaction
tests between SNP pairs from different gene regions (n=14). These SNPs were distributed on
15 chromosomes (see Supplementary Table 2 for markers and genes, Supplementary Table 3
for main-effect association results). The SNP-set based analysis did not reveal more genes/
regions of interest, as only two gene-specific p-values were < 0.05 (p=0.0024 and 0.01,
respectively, for IL10 and PTGIS) and both had been included for follow-up based on
single-variant analysis (Supplementary Table 3).
Stage 2
The main characteristics of the 4,783 MEC subjects (2,630 controls, 2,153 cases) are shown
in Table 1. There were 480 rectal, 910 right colon and 565 left colon cancer cases (counts
are mutually exclusive). We found one genotyped SNP, rs9858822 in the second intron of
PPARG on Chr 3, to be statistically significantly associated with CRC (Bonferroni-adjusted
P = 0.045, raw P = 1.48×10−4) (Table 2). The OR for each copy of allele C was 1.36 and the
genotypic ORs for AC and CC, vs. AA, were 1.24 (95% CI: 0.99–1.56) and 2.03 (95% CI:
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1.42–2.89), respectively. A log-additive genetic model was preferable based on the Bayesian
Information Criterion, compared to dominant, recessive or co-dominant models. The C
allele was common (MAF = 0.35) in African Americans but was relatively rare (MAF ≤
0.03) in the other 4 ethnic/racial groups, consistent with the HapMap data. As a result, the
observed association was mainly driven by the African Americans where the OR per C
allele was 1.36 (P = 4.9×10−4), whereas in the other four groups combined the OR was 1.19
(P = 0.53). This effect was not confounded by known CRC risk factors (further adjustment
resulted in <5% change in OR) or differed across ethnicity/race (Pinteraction = 0.99, perhaps
owing to the sparse data in some ethnic groups). Similarly, there did not seem to be
important effect modification by pack-years of smoking, BMI or regular aspirin use (raw
Pinteraction ≥ 0.08). For example, the OR (95% CI) for allele C was 1.28 (0.97 – 1.70) among
regular aspirin users (n=1,544) and 1.38 (1.08 – 1.76) among non-users (n=2,517), with
adjustment of other risk factors. Since rs9858822 was not genotyped or successfully imputed
in Stage 1 (as expected, given its low frequency in Europeans), no OR for the combined
studies was available.
The PPARG gene maps to 12,329,348 – 12,475,854 at 3p25.2 and SNPs in our data were
located from 12,330,730 to 12,479,552. LD structure for PPARG is complex and LD blocks
are difficult to define in the 1000 Genomes data (Supplementary Figures 1 to 3 for LD in
Europeans, Africans and East Asians in the 1000 Genomes Project). A few other SNPs
located nearby in the PPARG region showed suggestive associations in Stage 2 (Figure 1),
even though none passed the stringent Bonferroni adjustment. For example, the raw p-value
for rs4135304 (12,394,601 bp) and rs6778740 (12,398,636 bp) was 2.9×10−4 and 2.5×10−4,
respectively, and these SNPs were in high LD (r2 = 0.78 and 0.93) with rs9858822 in
African Americans. Logistic regression of all variants in PPARG conditional on rs9858822
did not reveal better candidate markers.
Rs9858822 lies in close proximity to a H3K4me1 ChIP-seq peak in the colon cancer cell
line HCT-116 (ENCODE, Stanford/Yale/USC/Harvard) (23). This histone modification is a
mark of a putative enhancer element. A few SNPs in high LD (r2 ≥ 0.69, |D′|=1) with
rs9858822 in the HapMap ASW (African Americans) are located within the putative
enhancer elements, such as rs9812856 (12,404,491), rs4135343 (12,447,964) and rs4135346
(12,448,498). Notably, rs4135343 is found at the 3′ end of a shorter PPARG splice variant,
in both H3K4me1 and H3K27ac ChIP-seq peaks, and directly downstream of many
transcription factor ChIP- seq signals (ENCODE, HAIB). These SNPs were imputed with
R2 > 0.91 only in African Americans in Stage 2 and were not analyzed in other ethnic
groups or in Stage 1. The p-values of association were 0.0002, 0.0014 and 0.0015,
respectively, for the three variants in African Americans.
Rs1801282 (Pro12Ala, C/G) in PPARG has been inconsistently associated with CRC in past
studies. In our data, it was genotyped in Stage 1 and was imputed in Stage 2 with R2 ≥ 0.8 in
all ethnic groups. However, the SNP was not associated with CRC in either stage, or when
the two studies were combined (all P’s > 0.4, Supplementary Table 5). In Stage 2, no
important association was observed in subsite-specific analyses (colon or rectum), or when
adjusted for BMI and diabetes status, or when stratified by ethnicity (all P’s > 0.05,
Supplementary Table 5).
Overall, we did not detect important interaction effects between SNPs and ethnicity or
known risk factors (BMI, pack-years of smoking or aspirin use) after multiple comparison
adjustment (Pinteraction’s ≥ 0.0003). Similarly, no strong heterogeneity by anatomical
location of the tumor was observed (Pheterogeneity’s > 0.005). All 31 SNPs with P < 0.05 in
Stage 2 main-effect analysis are shown in Supplementary Materials. Results from imputed
SNPs were similar to those from genotyped ones.
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Summary effect of non-significant genes in Stage 2
Among the 313 SNPs in genes other than PPARG where no variant was statistically
significantly associated with CRC, stepwise regression selected 12 SNPs with conditional p-
values < 0.05. The sum of the selected “risk” alleles (with OR>1) seemed associated with
CRC (χ2 = 63.3, P = 1.8 ×10−15). However, this effect was statistically non-significant from
permutation analysis (P = 0.26), when the so-called “winner’s curse” was corrected for.
DISCUSSION
Using a discovery and a validation step, both conducted in large and well-annotated studies,
we examined associations between colorectal cancer and common variation in 37 key genes
involved in the inflammation and immunity pathways. At the end of the validation step, only
one SNP in the second intron of PPARG, rs9858822 (12,411,238 on Chr 3), showed
statistically significant association after stringent Bonferroni-type multiple comparison
adjustment. This SNP is common (MAF 0.3) in African Americans, a population at high risk
for CRC, but rare in Europeans, Hispanics, East Asians and Native Hawaiians (MAF <
0.03).
PPARG encodes a nuclear transcription factor, PPARγ, that regulates target gene expression
upon ligand activation and through interaction with transcription co-factors. Natural ligands
for PPARγ include fatty acids and their derivatives. PPARγ has a predominant role in lipid
metabolism and adipocyte differentiation, as well as in maintaining glucose homeostasis and
insulin sensitivity, and in inflammation. PPARγ proteins are expressed in a broad range of
tissues including heart, skeletal muscle, small and large intestines, kidney, etc., depending
on the isoforms (24–26). Some links have been demonstrated between PPARγ and
colorectal tumor growth or differentiation, although the exact mechanism remains unclear
(27–31). PPARγ and its ligands have been shown to block pro-inflammatory genes in
activated macrophages, monocytes and colon cancer cell lines by inhibiting the nuclear
factor kappa-B (a master regulator of inflammatory processes), AP-1 and STAT pathways
(32–34). There is growing evidence that obesity/Type 2 diabetes, inflammation and cancer
(in particular CRC) are etiologically related (35, 36). Being at the crossroads of all these
processes, PPARγ may be a key element to understanding the pathophysiology of CRC.
The association of rs9858822 with CRC has not been reported before, probably owing to its
low frequency in non-African descent populations. Because of the extended and complex
LD structure in the PPARG region, we view this signal as an indication that the neighboring
PPARG region may contain causal risk variants for CRC, possibly representing an ethnic-
specific susceptibility locus in African Americans only. This signal is unlikely a chance
finding given the supporting evidence (small p-values) from neighboring SNPs (Figure 1).
The Pro12Ala polymorphism (rs1801282), the most studied PPARG variant to date, has
been consistently associated with Type 2 diabetes (37, 38). It has also been linked to CRC
risk, but inconsistently so. For example, a reduced risk was reported in a Spanish (12), a
Greek (39) and a Singapore-Chinese study (11); however, no effect was observed in several
other studies in the U.S. or among West Asians (13, 15, 40–42). Owing to the various
designs and study populations, it is hard to reconcile these past studies. As discussed before,
technical artifact during genotyping and the presence of multiple genetic ancestries within
individual studies (population stratification) (43) may not have been carefully controlled in
earlier candidate gene studies. We did not observe any statistically significant association
between Pro12Ala and CRC in our data, consistent with a recent systematic review of
colorectal cancer and genetic polymorphisms (44) that examined 15 SNPs in the
inflammation pathways, including two in PPARG, rs3856806 (C1431T) and rs1801282
(Pro12Ala). With more than 15,000 cases and 15,000 controls, rs1801282 was not
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associated with CRC (P-values > 0.35 for both heterozygous and homozygous genotypes)
(44); neither was rs3856806.
The strengths of our study include a comprehensive SNP tagging approach to capture
common genetic variation in key genes in the inflammation and immunity pathways,
rigorous genotype quality control procedures, large sample sizes in both stages, a replication
in a multi-ethnic population where ethnic-specific risk can be examined, the ability to
control for a variety of environmental risk factors and to examine gene-environment
interactions, and a strict multiple comparison adjustment approach. The value of conducting
association studies in multiethnic populations is evident from our result for rs9858822.
Given its low frequency in European-descent populations, the association with CRC (if
confirmed) could not have been easily detected if not tested in African Americans. The use
of Bonferroni correction based on the number of independent/effective markers estimated
from Keffective (21) has been shown to be conservative (45). This was especially so in our
analysis because we used the maximum estimate across five ethnic groups as the number of
independent/effective markers for each chromosome.
The limitations of our study include treating sibs in Stage 1 (in CCFR) as independent
subjects during imputation. To reduce the possibility of bias caused by this un-met
assumption, we restricted analysis to those markers imputed with a high R2 (> 0.9), which
eliminated many imputed markers from Stage 1 and prohibited us from combining the
results from both studies for these SNPs. However, this issue is not relevant to our findings
with rs9858822, because this variant is rare in whites and could not have been reliably
imputed even if the discovery phase had been conducted in unrelated subjects. Other
limitations included that some interactions may have been missed due to insufficient power
and/or model misspecification.
In summary, our findings from two large studies with different designs and populations
suggest that a new region in PPARG tagged by rs9858822 may constitute a susceptibility
locus for CRC. Replication in independent samples, especially in African Americans, is
warranted. In addition, a summary effect for the other studied genes (excluding PPARG) in
the inflammation and innate immunity pathways was not important, indicating little effects
of common variants in these genes with respect to colorectal cancer risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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P-values in the Multiethnic Cohort for genotyped and imputed in the PPARG region as a
function of genetic position (HG19), along with recombination rates (combined rates from
HapMap) that reflect local LD structure. The top hit SNP is shown as a red diamond. SNP
density is not ideal at some region because only SNPs with high imputation accuracy (R2 >
0.8) in ALL five ethnic groups were analyzed and R2 can vary a lot due to differences in
allele frequencies and linkage disequilibrium patterns across populations.
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